Biogen Inc.
210.73USD
-1.7700 (-0.83%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,478 | 2,279 | 2,535 | 2,646 | 2,431 | 2,455 | 2,466 | 2,465 |
| Cost of Revenue | 661 | 496 | 674 | 605 | 629 | 584 | 639 | 546 |
| Gross Profit | 1,817 | 1,784 | 1,860 | 2,041 | 1,802 | 1,871 | 1,827 | 1,919 |
| Operating Income | — | — | — | — | — | — | — | — |
| Net Income | 320 | -49 | 467 | 635 | 241 | 267 | 389 | 584 |
| EPS (Diluted) | $2.15 | $-0.35 | $3.17 | $4.33 | $1.64 | $1.83 | $2.66 | $4.00 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)